[go: up one dir, main page]

ES2061216T3 - Moleculas de ligacion de cd25. - Google Patents

Moleculas de ligacion de cd25.

Info

Publication number
ES2061216T3
ES2061216T3 ES91810166T ES91810166T ES2061216T3 ES 2061216 T3 ES2061216 T3 ES 2061216T3 ES 91810166 T ES91810166 T ES 91810166T ES 91810166 T ES91810166 T ES 91810166T ES 2061216 T3 ES2061216 T3 ES 2061216T3
Authority
ES
Spain
Prior art keywords
antibodies
molecules
linkage molecules
immunoconjugates
prophylaxis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91810166T
Other languages
English (en)
Inventor
Peter Lloyd Amlot
Arne Nalpon Akbar
Gunther Heinrich
Salvatore Cammisuli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Royal Free Hospital School of Medicine
Original Assignee
Sandoz AG
Royal Free Hospital School of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26296798&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2061216(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB909005962A external-priority patent/GB9005962D0/en
Priority claimed from GB909019323A external-priority patent/GB9019323D0/en
Application filed by Sandoz AG, Royal Free Hospital School of Medicine filed Critical Sandoz AG
Application granted granted Critical
Publication of ES2061216T3 publication Critical patent/ES2061216T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)

Abstract

NUEVOS ANTICUERPOS MONOCLONALES AL ANTIGENO CD25 ESTAN CARACTERIZADOS POR LA SECUENCIA AMINO ACIDA DE SUS REGIONES HIPERVARIABLES. INICIALMENTE PREPARADOS EN FORMA MURINA, PUEDEN SER CONVERTIDOS A FORMAS QUIMERICAS O HUMANIZADAS, INMUNOCONJUGADOS O FRAGMENTOS DE ANTICUERPOS ( DESCRITOS GENERALMENTE COMO MOLECULAS DE ENLACE). LOS PRODUCTOS SON UTILES PARA LA PROFILAXIS O TRATAMIENTO DEL RECHAZO DE TRANSPLANTE, PARTICULARMENTE EN COMBINACION CON OTROS ANTICUERPOS A CELULAS-T ACTIVADAS, POR EJEMPLO ANTICUERPOS CD 7.
ES91810166T 1990-03-16 1991-03-13 Moleculas de ligacion de cd25. Expired - Lifetime ES2061216T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909005962A GB9005962D0 (en) 1990-03-16 1990-03-16 Improvements in or relating to organic compounds
GB909019323A GB9019323D0 (en) 1990-09-05 1990-09-05 Improvements relating to immunosuppression

Publications (1)

Publication Number Publication Date
ES2061216T3 true ES2061216T3 (es) 1994-12-01

Family

ID=26296798

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91810166T Expired - Lifetime ES2061216T3 (es) 1990-03-16 1991-03-13 Moleculas de ligacion de cd25.

Country Status (23)

Country Link
US (2) US6521230B1 (es)
EP (1) EP0449769B1 (es)
JP (1) JP2585475B2 (es)
AT (1) ATE98655T1 (es)
AU (1) AU635401B2 (es)
CA (1) CA2038279C (es)
CY (1) CY1977A (es)
DE (2) DE19975033I2 (es)
DK (1) DK0449769T3 (es)
ES (1) ES2061216T3 (es)
FI (3) FI103131B1 (es)
HK (1) HK53797A (es)
HU (2) HUT60768A (es)
IE (1) IE65062B1 (es)
IL (1) IL97545A (es)
LU (1) LU90383I2 (es)
MY (1) MY106161A (es)
NL (1) NL990008I2 (es)
NZ (1) NZ237434A (es)
PL (1) PL170321B1 (es)
PT (1) PT97034B (es)
SA (1) SA92120358B1 (es)
TW (1) TW213486B (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6329508B1 (en) 1989-09-07 2001-12-11 Alkermes, Inc. Transferrin receptor reactive chimeric antibodies
US5977307A (en) * 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
WO1993010819A1 (en) * 1991-11-26 1993-06-10 Alkermes, Inc. Process for the preparation of transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US5672683A (en) * 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
US6106834A (en) 1993-06-02 2000-08-22 Research Corporation Technologies, Inc. Use of anti-CD45 leukocyte antigen antibodies for immunomodulation
US6024957A (en) * 1993-06-02 2000-02-15 Research Corporation Technologies, Inc. Immunomodulators and methods for the prevention and reversal of organ transplant rejection using same
US6015555A (en) * 1995-05-19 2000-01-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US7033589B1 (en) * 1997-02-20 2006-04-25 Biogen Idec Ma Inc. γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
US6893636B2 (en) * 1997-02-20 2005-05-17 Biogen Idec Ma Inc. Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
AU747260B2 (en) 1997-07-25 2002-05-09 Nichia Chemical Industries, Ltd. Nitride semiconductor device
AUPP221098A0 (en) * 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
AU5728699A (en) * 1998-07-27 2000-02-21 Amlot, Peter Lloyd Use of cd25 binding molecules in the treatment of rheumatoid arthritis or skin diseases
WO2000025816A1 (en) * 1998-10-30 2000-05-11 The University Of Miami Treatment of hepatitis c by administration of anti-il-2 receptor monoclonal antibody and an antiviral compound
US6406695B1 (en) 1998-10-30 2002-06-18 University Of Miami Treatment of hepatitis C by administration of anti-IL-2 receptor monoclonal antibody
GB9825632D0 (en) 1998-11-23 1999-01-13 Novartis Ag Organic compounds
FR2793691B1 (fr) * 1999-05-21 2003-10-03 Hippocampe Utilisation d'anticorps reconnaissant le recepteur de l'interleukine-2 dans la prevention et/ou le traitement des infections par les virus du sida
GB0007911D0 (en) * 2000-03-30 2000-05-17 Novartis Ag Organic compounds
CZ20032672A3 (cs) * 2001-04-06 2003-12-17 University Of Bristol CD25 vazebná molekula pro použití při prevenci nebo léčení některých nemocí u pacientů rezistentních na léčbu steroidy
US7365168B2 (en) * 2002-10-15 2008-04-29 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7361740B2 (en) * 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
JP4033390B2 (ja) * 2002-10-30 2008-01-16 独立行政法人科学技術振興機構 不死化ナチュラルキラー細胞株
NZ540555A (en) 2002-11-15 2008-04-30 Genmab As Antibody therapeutics for treatingand/or preventing diseases associated with cells expressing CD25, including autoimmune diseases, inflammatory and hyperproliferative skin disorders
EP1460088A1 (en) 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
JP2007531707A (ja) * 2003-10-15 2007-11-08 ピーディーエル バイオファーマ， インコーポレイテッド ＩＧの重鎖定常領域の位置２５０、３１４および／または４２８の変異誘発によるＦｃ融合タンパク質血清半減期の改変
CU23297A1 (es) * 2004-11-16 2008-07-24 Ct De Inmunologa A Molecular Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer
GB0507696D0 (en) * 2005-04-15 2005-05-25 Novartis Ag Organic compounds
DK2270050T3 (da) 2005-12-30 2013-08-12 Merck Patent Gmbh Anti-CD19-antistoffer med nedsat immunogenicitet
KR20100135257A (ko) 2008-03-13 2010-12-24 바이오테스트 아게 질병 치료제
ES2569217T3 (es) 2008-03-13 2016-05-09 Biotest Ag Agente para tratar enfermedades
ES2610327T3 (es) 2008-03-13 2017-04-27 Biotest Ag Régimen de dosificación de anticuerpos anti-CD4 para el tratamiento de enfermedades autoinmunitarias
ES2622366T3 (es) 2009-10-26 2017-07-06 F. Hoffmann-La Roche Ag Procedimiento para la producción de una inmunoglobulina glucosilada
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
US20140359902A1 (en) 2011-12-16 2014-12-04 Synthon Biopharmaceuticals B.V. EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED
DK2839860T3 (da) 2012-10-12 2019-06-17 Medimmune Ltd Pyrrolobenzodiazepiner og konjugater deraf
ES2687439T3 (es) 2013-03-13 2018-10-25 Medimmune Limited Pirrolobenzodiazepinas y conjugados de las mismas
CN106687141A (zh) 2014-09-10 2017-05-17 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其缀合物
CN107148285B (zh) 2014-11-25 2022-01-04 Adc治疗股份有限公司 吡咯并苯并二氮杂䓬-抗体缀合物
US9993452B2 (en) 2014-12-05 2018-06-12 Vireo Systems, Inc. Compositions and methods for treatment of inflammation
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
US20170157215A1 (en) 2015-12-04 2017-06-08 Jomoco, Corp. Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
CN109862919A (zh) 2016-10-11 2019-06-07 免疫医疗有限公司 抗体-药物缀合物联合免疫介导的治疗剂
JP7402691B2 (ja) 2017-04-20 2023-12-21 アーデーセー セラピューティクス ソシエテ アノニム 抗ｃｄ２５抗体薬物複合体による併用療法
EP3796942A1 (en) 2018-05-23 2021-03-31 ADC Therapeutics SA Molecular adjuvant
GB201811364D0 (en) 2018-07-11 2018-08-29 Adc Therapeutics Sa Combination therapy
CA3135992C (en) * 2019-06-10 2024-02-13 Shandong Boan Biotechnology Co., Ltd. Anti-cd25 antibody and application thereof
GB201917254D0 (en) 2019-11-27 2020-01-08 Adc Therapeutics Sa Combination therapy
WO2022079211A1 (en) 2020-10-16 2022-04-21 Adc Therapeutics Sa Glycoconjugates
WO2022165419A1 (en) 2021-02-01 2022-08-04 Kyverna Therapeutics, Inc. Methods for increasing t-cell function
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
US20230056336A1 (en) 2021-04-15 2023-02-23 Kyverna Therapeutics, Inc. Methods and compositions for treating disease using targeted foxp3+cd4+ t cells and cellular suicide agents
JP2024541058A (ja) 2021-11-03 2024-11-06 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． 抗体の特異的共役
CN114957473B (zh) * 2022-04-25 2023-05-16 苏州旭光科星抗体生物科技有限公司 一种对可溶性cd25蛋白含量检测的酶联免疫检测试剂盒
JP2025525430A (ja) 2022-07-01 2025-08-05 ニューロジーン・インコーポレイテッド Ｔ制御性細胞を優先的に刺激するためのｎｅｏ－２／１５バリアント及びそれらの使用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8605316D0 (en) * 1986-03-04 1986-04-09 Royal Free Hosp School Med Immunosuppression
GB2188941B (en) 1986-04-14 1990-06-06 Bayer Ag Monoclonal antibodies recognizing human interleukin-2-receptor
EP0319333B1 (en) * 1987-12-02 1994-07-20 Becton, Dickinson and Company Method for the prevention of graft versus host disease
AU631545B2 (en) * 1988-04-15 1992-12-03 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
DE3815472A1 (de) 1988-05-06 1989-11-16 Centre Regional De Transfusion Monoklonaler antikoerper und seine verwendung
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6013256A (en) 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation

Also Published As

Publication number Publication date
DE69100768D1 (de) 1994-01-27
LU90383I2 (fr) 1999-06-07
PT97034A (pt) 1991-10-31
DE69100768T2 (de) 1994-05-11
ATE98655T1 (de) 1994-01-15
TW213486B (es) 1993-09-21
JP2585475B2 (ja) 1997-02-26
EP0449769B1 (en) 1993-12-15
DK0449769T3 (da) 1994-02-21
NZ237434A (en) 1992-08-26
NL990008I2 (nl) 1999-10-01
FI103131B (fi) 1999-04-30
FI19991788L (fi) 1999-08-23
FI911275A0 (fi) 1991-03-14
IE910867A1 (en) 1991-09-25
FI911275L (fi) 1991-09-17
PL289436A1 (en) 1992-02-24
DE19975033I2 (de) 2007-01-04
JPH04316600A (ja) 1992-11-06
IL97545A (en) 2000-06-29
FI981799A0 (fi) 1998-08-21
PL170321B1 (pl) 1996-11-29
FI981799L (fi) 1998-08-21
NL990008I1 (nl) 1999-06-01
US6383487B1 (en) 2002-05-07
US6521230B1 (en) 2003-02-18
CA2038279C (en) 1999-03-09
HU211885A9 (en) 1995-12-28
HUT60768A (en) 1992-10-28
HK53797A (en) 1997-05-02
IE65062B1 (en) 1995-10-04
AU635401B2 (en) 1993-03-18
FI104047B1 (fi) 1999-11-15
CY1977A (en) 1997-09-05
FI103131B1 (fi) 1999-04-30
HU910761D0 (en) 1991-09-30
MY106161A (en) 1995-03-31
FI104047B (fi) 1999-11-15
PT97034B (pt) 1998-07-31
IL97545A0 (en) 1992-06-21
SA92120358B1 (ar) 2004-01-25
EP0449769A1 (en) 1991-10-02
AU7290991A (en) 1991-09-19
CA2038279A1 (en) 1991-09-17
FI19991788A7 (fi) 1999-08-23

Similar Documents

Publication Publication Date Title
ES2061216T3 (es) Moleculas de ligacion de cd25.
ATE208820T1 (de) Humanisierte antikoerper
ES2087923T3 (es) Anticuerpo monoclonal reactivo con un nuevo determinante hla sobre moleculas del mhc de la clase i y procedimiento para la activacion de linfocitos.
ES2074701T3 (es) Anticuerpo recombinante especifico cd3.
PE20020972A1 (es) Anticuerpos recombinantes asociados a gangliosidos
WO1990010709A3 (en) Monoclonal antibodies for metallic cations on small molecules
RU2005132389A (ru) Гуманизированное анти-cd4 антитело с иммунодепрессивными свойствами
AR079458A2 (es) Anticuerpo monoclonal quimerico que se une a cd45
KR910016346A (ko) 광견병 바이러스에 대한 사람 모노클로날 항체, 이의 제조방법 및 용도
KR900701318A (ko) 항-사람 고분자량- 흑색종 관련 항원에 대한 항-이디오 타입 항체
KR890016165A (ko) 수도모나스 아에루기노사(Pseudomonas aeruginosa)에 대한 모노클로날 항체, 이의 제조방법 및 용도
NO883854D0 (no) Monoklonalt antistoff og fremgangsmaate for dets fremstilling.
DE3580524D1 (de) Monoklonaler antikoerper geeignet zur spezifischen unterscheidung von humanen hepatokarzinomzellen.
KR930019820A (ko) 모노클로날 항-강글리오사이드 항체, 이의 제조방법 및 종양 치료제로서의 용도
DK0472498T3 (da) Monoklone antistoffer mod Leptosphaeria.
MY104917A (en) Monoclonal antibodies and methods for diagnosis of phytophora infection
GR890100333A (en) Antihuman antigen antibodies

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 449769

Country of ref document: ES

SPCF Request for supplementary protection certificate filed

Free format text: BASILIXIMAB (SIMULECT)

Spc suppl protection certif: C9900015

Filing date: 19990408

SPCG Supplementary protection certificate granted

Free format text: BASILIXIMAB (SIMULECT)

Spc suppl protection certif: C9900015

Filing date: 19990408

Expiry date: 20131009

Effective date: 20010814